Hunt J E, McNeil H P, Morgan G J, Crameri R M, Krilis S A
University of New South Wales, School of Medicine, St George Hospital Kogarah, Sydney, Australia.
Lupus. 1992 Feb;1(2):75-81. doi: 10.1177/096120339200100204.
Anticardiolipin antibodies (aCL) purified from patients with autoimmune disease have recently been shown to interact with a phospholipid-binding plasma protein, beta 2-glycoprotein I (beta 2-GPI). The aim of this study was to determine whether aCL purified from patients with infection also interact with beta 2-GPI. aCL purified from 23 patients with malaria, infectious mononucleosis, tuberculosis, hepatitis A or syphilis did not require the presence of beta 2-GPI to bind cardiolipin (CL). In contrast, aCL were purified from 11 out of 12 patients with autoimmune disease that bound CL only in the presence of beta 2-GPI. Thrombotic complications appear to be associated with aCL occurring in autoimmune disease but not with aCL associated with infections. We postulate that this increased risk of thrombosis in the autoimmune group may be due to the presence of aCL that bind CL in association with beta 2-GPI, a plasma protein with anticoagulant activity.
最近研究表明，从自身免疫性疾病患者体内纯化出的抗心磷脂抗体（aCL）可与磷脂结合血浆蛋白β2糖蛋白I（β2-GPI）相互作用。本研究旨在确定从感染患者体内纯化出的aCL是否也与β2-GPI相互作用。从23例疟疾、传染性单核细胞增多症、结核病、甲型肝炎或梅毒患者体内纯化出的aCL在结合心磷脂（CL）时并不需要β2-GPI的存在。相比之下，从12例自身免疫性疾病患者中的11例体内纯化出的aCL仅在有β2-GPI存在时才能结合CL。血栓形成并发症似乎与自身免疫性疾病中出现的aCL有关，而与感染相关的aCL无关。我们推测，自身免疫组中这种血栓形成风险增加可能是由于与具有抗凝活性的血浆蛋白β2-GPI结合CL的aCL的存在。
